Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00316771
Registration number
NCT00316771
Ethics application status
Date submitted
20/04/2006
Date registered
21/04/2006
Date last updated
2/11/2016
Titles & IDs
Public title
A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.
Query!
Secondary ID [1]
0
0
PA18439
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - P38 Inhibitor (4) 150mg
Treatment: Drugs - P38 Inhibitor (4) 25mg
Treatment: Drugs - P38 Inhibitor (4) 300mg
Treatment: Drugs - P38 Inhibitor (4) 50mg
Treatment: Drugs - P38 Inhibitor (4) 75mg
Treatment: Drugs - Placebo
Experimental: P38 Inhibitor (4) 150mg -
Experimental: P38 Inhibitor (4) 25mg -
Experimental: P38 Inhibitor (4) 300mg -
Experimental: P38 Inhibitor (4) 50mg -
Experimental: P38 Inhibitor (4) 75mg -
Placebo Comparator: Placebo -
Treatment: Drugs: P38 Inhibitor (4) 150mg
150mg po qd
Treatment: Drugs: P38 Inhibitor (4) 25mg
25mg po bid
Treatment: Drugs: P38 Inhibitor (4) 300mg
300mg po qd
Treatment: Drugs: P38 Inhibitor (4) 50mg
50mg po qd
Treatment: Drugs: P38 Inhibitor (4) 75mg
75mg po bid
Treatment: Drugs: Placebo
po bid
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of patients with ACR 20 response
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Percentage of patients with ACR 50/70 response
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Change in ACR core set, DAS 28, HAQ disability index, SF-36, withdrawals, AEs, lab parameters.
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Throughout study
Query!
Eligibility
Key inclusion criteria
- adult patients >=18 years of age;
- active rheumatoid arthritis;
- current inadequate clinical response to methotrexate.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- receiving any other disease-modifying anti-rheumatic drug, with the exception of
hydroxychloroquine or chloroquine.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
374
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Caboolture
Query!
Recruitment hospital [2]
0
0
- Fitzroy
Query!
Recruitment hospital [3]
0
0
- Kippa Ring
Query!
Recruitment postcode(s) [1]
0
0
4510 - Caboolture
Query!
Recruitment postcode(s) [2]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [3]
0
0
4021 - Kippa Ring
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nebraska
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Jersey
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Mexico
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Dakota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oklahoma
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oregon
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Dakota
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Tennessee
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Texas
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Washington
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Wisconsin
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Curitiba
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Goiania
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Sao Paulo
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Alberta
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Manitoba
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Newfoundland and Labrador
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Ontario
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Quebec
Query!
Country [34]
0
0
Estonia
Query!
State/province [34]
0
0
Tallinn
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Bad Nauheim
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Berlin
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Erfurt
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Erlangen
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Leipzig
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Muenchen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Wiesbaden
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Athens
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Heraklion
Query!
Country [44]
0
0
Greece
Query!
State/province [44]
0
0
Ioannina
Query!
Country [45]
0
0
Greece
Query!
State/province [45]
0
0
Thessaloniki
Query!
Country [46]
0
0
Ireland
Query!
State/province [46]
0
0
Dublin
Query!
Country [47]
0
0
Mexico
Query!
State/province [47]
0
0
Guadalajara
Query!
Country [48]
0
0
Mexico
Query!
State/province [48]
0
0
Mexico City
Query!
Country [49]
0
0
Mexico
Query!
State/province [49]
0
0
Monterrey
Query!
Country [50]
0
0
Mexico
Query!
State/province [50]
0
0
San Luis Potosi
Query!
Country [51]
0
0
New Zealand
Query!
State/province [51]
0
0
Auckland
Query!
Country [52]
0
0
New Zealand
Query!
State/province [52]
0
0
Christchurch
Query!
Country [53]
0
0
New Zealand
Query!
State/province [53]
0
0
Lower Hutt
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Elblag
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Sopot
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Szczecin
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Torun
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Warszawa
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
Bloemfontein
Query!
Country [60]
0
0
South Africa
Query!
State/province [60]
0
0
Cape Town
Query!
Country [61]
0
0
South Africa
Query!
State/province [61]
0
0
Durban
Query!
Country [62]
0
0
South Africa
Query!
State/province [62]
0
0
Johannesburg
Query!
Country [63]
0
0
South Africa
Query!
State/province [63]
0
0
Pretoria
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Barcelona
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Córdoba
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
La Coruna
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
La Laguna
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Lugo
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Madrid
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Sabadell
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
Basingstoke
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Cannock
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Harrogate
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
Leeds
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Newcastle Upon Tyne
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Southampton
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
Wigan
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This 6 arm study will evaluate the efficacy and safety of different doses of P38 Inhibitor
(4) in patients with RA currently having an inadequate clinical response to methotrexate.
Patients will be randomized to receive P38 Inhibitor (4) (50,150 or 300 qd po,and 25 or 75
bid po) or placebo, and will remain on the stable dose of methotrexate. The anticipated time
on study treatment is <3 months, and the target sample size is 100-500 individuals.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00316771
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00316771
Download to PDF